Cancer Genetics, Inc. (CGIX) Expands Relationship With Roche Servicios S.A.
RUTHERFORD, N.J., Sept. 18, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, expanded its relationship with Roche Servicios S.A., an affiliate of the Swiss drug maker Roche. The companies will work together to develop workshops and training programs designed to drive adoption of biomarker-based cancer diagnostics at hospitals and cancer centers throughout Central America and the Caribbean.
Panna Sharma, CEO of CGI, stated, "This new initiative is an extension of our existing work with Roche Servicios, and it aligns with our focus on bringing our genomic testing to the community setting."
Since August 2012, CGI has performed highly complex testing services for Roche Servicios intended to provide information for the diagnosis and prognosis of cancer patients. These services help Roche Servicios deliver quality results to clinicians based in 14 different locations covering Central America and the Caribbean.
"Cancer Genetics' advanced technologies provide crucial genomic information that can be used for better outcome prediction and targeted treatment," stated Alvaro Soto, Central America and Caribbean General Manager of Roche Servicios. "We've seen great results in our work with Cancer Genetics. Together we've already affected hundreds of lives by targeting early therapeutics faster. By expanding our relationship, we are strengthening our ability to provide patients the best service possible."
Lan Wang, M.D., medical director of CGI, stated, "The workshops and training programs we are implementing will improve access to accurate genetic-based diagnostics, positively impacting therapeutic decision making in cancer care throughout the region, while adhering to the highest industry standards."
Mr. Sharma added: "We are extremely pleased to work with Roche on improving cancer care in the region. Building on our Expand Dx" outreach program, our joint efforts are well-positioned to accelerate the adoption of targeted tools to fight cancer."
Roche Servicios plans to evaluate other CGI programs that can increase its scope of services and range of patients being serviced.
CGI's Expand Dx" program is designed to enhance and expand community access to cancer diagnostics and personalized cancer treatment by developing outreach to hospitals and cancer centers. Expand Dx" builds on a laboratory's capabilities to increase efficiency and drive revenue, helping community facilities stay competitive and grow in today's evolving market.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com .
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 firstname.lastname@example.orgSource: Cancer Genetics 2013 GlobeNewswire, Inc.